Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, is pleased to announce the availability of its high-affinity Anti Venom Antibodies to researchers studying snakebite envenomation. These antibodies hold immense potential for improved snakebite treatments.
Snakebite envenomation is considered a neglected tropical disease that affects tens of thousands of people each year. Snake venom is an extremely complex mixture consisting mainly of proteins (±90-95%), in addition to peptides, carbohydrates, fragments of nucleic acid derivatives, metal ions, biogenic amines, lipids and free amino acids, which have different biological activities.
In general, viperid venoms are cytotoxic, hematotoxic, and occasionally myotoxic due to the fact that snake venom metalloproteinases (SVMPs) weaken capillaries and blood vessel walls, leading to hemorrhage. SVMPs and phospholipase A2 (PLA2) also cause tissue damage at the site of the bite, resulting in muscle weakness and tissue necrosis. On the other hand, elapid venoms (and a small percentage of viperid venoms) contains neurotoxins (which primarily cause systemic neurotoxicity) that block neuromuscular signaling. These toxins eventually block signaling to the lung muscles, causing respiratory paralysis and death.
Currently, the recommended treatment for snakebite is the use of antivenom or serum therapy, which treats snakebite by neutralizing the venomous toxins produced by snake venom. The most important clinical determinants in the treatment of snakebite are the type of antivenom to be used and the dose of antivenom. The specificity and dosage of antivenom depend on the accurate diagnosis of the snake. This requires the use of immunology-based assays, such as ELISA, to detect and quantify specific venoms to confirm the identity of the snake. In addition, the free venom of the patient is measured after therapy to determine if sufficient antivenom has been administered. Immunoassays can also be used to evaluate the cross-reactivity of antivenoms.
Effective antivenom therapy is critical to saving lives, but accurate diagnosis and appropriate antivenom selection are often challenging. Creative Diagnostics now offers a comprehensive portfolio of anti venom antibodies that target a broad range of toxins found in snake venom, providing researchers with valuable tools for the development of new and improved antivenom therapies. These new anti-venom polyclonal antibodies are specifically designed for research applications and are not intended for diagnostic use, such as the Sheep Anti-Vipera l atastei Venom PolyclonalAntibody (DPAB-JX2371341).
Creative Diagnostics is committed to advancing research in snakebite treatment. The release of these anti-venom antibodies demonstrates its commitment to advancing snakebite management to accelerate scientific research and development. Creative Diagnostics also offers custom antibody services and bulk production to support large-scale research efforts.
Creative Diagnostics’ Anti Venom Polyclonal Antibodies are meticulously designed to target specific snake venom toxins, making them ideal for research applications. For more information on the new antibodies, please visit https://www.creative-diagnostics.com/anti-venom-polyclonal-antibody.htm.
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers’ assay development and manufacturing needs.
Be the first person to like this.
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is pleased to announce the launch of its state-of-the-art Immunofluorescence Assay (IFA) Testing services to support virology research. The new services provide researchers with a critical tool to confirm the presence or absence of antibodies against specific viruses, commonly employed in an ELISA or MFIA test.
The IFA is a standard technique in virology and is commonly used to confirm the presence of infectious antibodies to specific viral antigens. The technique is typically used after an enzyme-linked immunosorbent assay (ELISA) or multiple fluorescence immunoassay (MFIA) to confirm a positive result. Creative Diagnostics is committed to providing researchers with the most advanced technology and expertise to advance antiviral research. These new IFA testing services offer a cost-effective and reliable solution and unparalleled support in IFA development and application, helping researchers accelerate their antiviral programs.
Specifically, in the first incubation step, specific antibodies in the diluted sample bind to the solid-bound antigen. In the next step, a fluorescein-labeled antibody (conjugate) binds to the specific antibody in the sample. The complex is clearly visible under a fluorescence microscope when excited at the appropriate wavelength. Test processing can be manual, semi-automated, or fully automated.
Creative Diagnostics’ IFA testing services offer several advantages. They are relatively inexpensive to perform, and the morphology and location of the fluorescence can be evaluated to distinguish specific from non-specific reactions. Additionally, these assays are validated with a panel of titered sera to ensure sensitivity, and they allow the detection of IgG or IgM antibodies. Finally, the presence of positive and negative control cells provides a built-in check for the accuracy of the test. These IFA testing services offer a powerful combination of experience, flexibility, and accuracy to accelerate critical research efforts.
In addition, Creative Diagnostics has a team of experienced scientists who are experts in IFA development and understand the importance of accurate and reliable IFA tests. By combining its IFA testing expertise with its in-depth knowledge of antiviral research, Creative Diagnostics is dedicated to working closely with clients to develop assays that meet their specific needs.
Utilizing cutting-edge technology, Creative Diagnostics offers a wide range of antiviral services to evaluate the inhibitory activity of inhibitor candidates. Moreover, a variety of customized antiviral assays are available to elucidate the action mechanism of novel antiviral drugs. Creative Diagnostics has developed and optimized novel antiviral assays for multiple viruses. All antiviral assays can be tested for cytotoxicity in transformed or primary cells to ensure accurate and reliable results.
Creative Diagnostics offers researchers IFA Testing services to accelerate breakthroughs in the field of virology. For more information about the IFA Testing, please visit https://antiviral.creative-diagnostics.com/ifa-testing.html.
About Creative Diagnostics
Headquartered in New York, Creative Diagnostics is a consulting and experimental service provider specializing in virology and microbiology. The company provides comprehensive solutions to conquer obstacles in virology and microbiology research, from high-security infrastructure provision, biosafety regulation elucidation, to expert viral system assistance.
Creative Diagnostics, a leading manufacturer and supplier of antibodies, small molecule conjugates and critical assay reagents for food, feed, environmental and toxicological sample analysis, announced the launch of its comprehensive line of Fumonisin Test Reagents, including conjugates, antibodies and test kits. These new reagents offer reliable and accurate solutions for detecting the harmful mycotoxin, fumonisin, in various food and grain products.
Fumonisins are mycotoxins produced by several Fusarium species, including Fusarium verticillioides and Fusarium proliferatum. These compounds are inhibitors of ceramide synthetase, preventing membrane biosynthesis. In humans, fumonisins have been linked to esophageal cancer. For animals, including horses, pigs, poultry, and cattle, fumonisins can cause heart and liver damage, growth retardation, and kidney and liver cancer. Like other mycotoxins, fumonisins harm animals and humans through the food, feed and pet food supply chain. Corn and small grains such as wheat, oats and barley are the main crops affected.
Exposure to fumonisin can cause a variety of health problems in humans and animals, thus the detection of this mycotoxin is of critical importance and requires reliable analytical methods. Creative Diagnostics is committed to developing quality assays to support the development of mycotoxin detection. After years of research by its technical staff, Creative Diagnostics has successfully developed a range of antigens and antibodies for immunoassays and established enzyme-linked immunosorbent assay (ELISA) and lateral flow immunoassay (LFIA) detection platforms.
Creative Diagnostics now offers a variety of Fumonisin Test Reagents to provide a reliable and sensitive method for detecting fumonisin in food and grain products, helping to ensure the safety of the food supply. These new Fumonisin Test Reagents are designed for use in a variety of analytical techniques, including ELISA, HPLC, and PCR. The company also offers a variety of other mycotoxin test kits and custom assay development services to meet the specific needs of its customers.
For example, the Fumonisin B1 Test (DTS437) is a competitive immunoassay for the semi-quantitative detection of Fumonisin B1 in grain or feed. The kit can be stored at room temperature (2-30°C) and is stable until the expiration date (18 months) marked on the foil pouch. In addition, the Fumonisin Plate Kit (DEIA6848) can be used for the quantitative analysis of fumonisin in corn, corn meal, corn germ meal, corn gluten meal, and corn/soy blend. These Fumonisin Test Reagents are easy to use and can be performed in a variety of laboratory settings.
Creative Diagnostics offers a comprehensive portfolio of Fumonisin Test Reagents for the detection of fumonisin in food products, contributing to consumer safety and regulatory compliance in the food industry. For more information and to explore Creative Diagnostics’ food safety products, please visit https://www.creative-diagnostics.com/food-analysis/tag-fumonisin-35.htm.
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, small molecule conjugates and critical assay reagents for the analysis of food, feed, environmental and toxicological samples. Its product portfolio covers a wide range of analytes including mycotoxins, drug residues, pesticides, contaminants, food allergens, food pathogens and vitamins. The company also assists customers in the rapid development, manufacture and commercialization of small molecule antigens, antibodies and food safety lateral flow strips for any market segment.
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, is pleased to announce the launch of its cutting-edge Kanamycin ELISA Kit. This innovative kit enables the rapid and accurate detection of kanamycin residues in various biological products.
Biopharmaceuticals are a class of drugs that are typically produced in living organisms and can be used to treat a wide range of diseases. Biopharmaceutical samples include hormones, enzymes, monoclonal antibodies, vaccines, and blood factors, each of which face different challenges during drug development and production, including process-related residual impurities and their levels in the final biopharmaceutical product.
The use of appropriate concentrations of antibiotics during cell culture can prevent contamination as well as morphological or physiological changes caused by contamination. In addition, certain antibiotics are used to screen transfected/transgenic cells. Therefore, antibiotics are common cell culture-derived impurities in biomanufacturing processes.
Kanamycin or Kanamycin A is a bactericidal aminoglycoside antibiotic available in oral, intravenous and intramuscular forms for the treatment of a wide range of infections and tuberculosis. Kanamycin is isolated from Streptomyces kanamycinensis and its most commonly used form is kanamycin sulfate. It is commonly used as an antibiotic in cell culture processes. Due to the potent effects of kanamycin on humans during the manufacturing process and in the finished drug product, regulatory agencies around the world have limited and quantified kanamycin residues. Residues of kanamycin during the manufacture of biologics can cause abnormal reactions in humans and therefore strict MRLs have been established.
Creative Diagnostics now provides researchers with a rapid, accurate, and easy-to-use method for detecting kanamycin residues in biological products. The analytical sensitivity of the Kanamycin ELISA kit has been determined to be 0.5 ng/mL. The standards / linear graph range is 0.5-40.5 ng/mL. It allows precise measurement of Kanamycin levels in various samples and can greatly reduce the operator error in the detection process.
This ELISA kit has been designed for the detection of Kanamycin based on the principle of the “indirect competitive” enzyme immunoassay. The microtiter plate is coated with a capture antigen linked to BSA. Kanamycin in the sample competes with the antigen on the microplate for antibodies. After addition of the enzyme conjugate, chromogenic substrate is used and the signal is measured by spectrophotometer. The absorbance is inversely proportional to the concentration of kanamycin in the sample. It is noted that this kit is for research and laboratory use only and is not intended for diagnostic, therapeutic, drug, home or other usage.
Creative Diagnostics offers Kanamycin ELISA Kit for the quantitative and qualitative analysis of kanamycin residues in biological samples. For more information on the new product, please visit https://www.creative-diagnostics.com/Kanamycin-ELISA-Kit-3589-464.htm.
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers’ assay development and manufacturing needs.
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its comprehensive portfolio of ELISA Based Assays for vaccine development and bioprocess applications.
Vaccine development involves a variety of assays to support vaccine research and development, from early preclinical studies to final production, quality control and lot release. ELISA-based assays are widely used to measure vaccine titers, carrier titers, purity, affinity and potency, as well as immunogenic responses in animals and humans.
ELISA-based immunoassays are the gold standard for various aspects of vaccine bioanalysis, including quantification of antigenic epitopes, detection of contaminants, and determination of vaccine efficacy (e.g., vaccine titer and immunogenicity). They are crucial for vaccine bioanalysis, but limitations exist, such as high reagent and sample consumption, diverse sample types, and time-consuming procedures. To address these issues, researchers are exploring improved immunoassays to minimize the use of valuable reagents (e.g., vaccine candidate molecules) and small animal samples, handle different sample types such as serum, plasma, and preparations containing aluminum particles and emulsions, and reduce hands-on time to shorten assay development time.
Creative Diagnostics is committed to providing innovative and reliable solutions to advance vaccine development and bioprocess efficiency. With its expertise in ELISA-based assays, the company empowers researchers and manufacturers to effectively measure vaccine titer, vector titer, purity, potency, and immunogenic response, ultimately contributing to the development of safe and effective vaccines.
For example, Creative Diagnostics can help researchers determine viral vector particle concentrations (titers). Viral vector vaccines are live viruses genetically engineered to express one or more heterologous antigens. Determination of vector particle concentration is an important step in the development and production of such vaccines. Creative Diagnostics now offers high quality ELISA kits for the determination of titers of a range of AAV serotypes or lentiviruses (p24).
In addition, Creative Diagnostics can assist in the detection of antigen-specific antibodies in serum and in antigen quantification and comparison of vaccine lots for release testing. By providing expertise and comprehensive solutions, Creative Diagnostics enables researchers and manufacturers to advance vaccine development and bioprocess efficiency.
Creative Diagnostics also offers a comprehensive range of high-quality ELISA kits for the detection of viral antigens and antibodies. With extensive experience in custom assay development and validation, the Creative Diagnostics team of experts ensures customized solutions to support customer needs. Utilizing extensive reference control and standard materials, Creative Diagnostics delivers reliable qualitative and quantitative testing. Additionally, the company's holistic study design considers pretesting requirements, sampling modes, detection methods, and assay sensitivities, resulting in effective viral ELISA-based assays.
By offering a comprehensive suite of ELISA-based solutions and unparalleled scientific expertise, Creative Diagnostics empowers researchers and developers to streamline their vaccine development and bioprocess workflows. For more information on the ELISA Based Assays, please visit https://antiviral.creative-diagnostics.com/elisa-based-assays.html.
About Creative Diagnostics
Headquartered in New York, Creative Diagnostics is a consulting and experimental service provider specializing in virology and microbiology. The company provides comprehensive solutions to conquer obstacles in virology and microbiology research, from high-security infrastructure provision, biosafety regulation elucidation, to expert viral system assistance.
Creative Diagnostics, a leading manufacturer and supplier of antibodies, small molecule conjugates and critical assay reagents for food, feed, environmental and toxicological sample analysis, proudly announces the availability of a comprehensive portfolio of Vomitoxin Test Reagents for the detection of Deoxynivalenol in food products, including ELISA Kits, antibodies and Immunoaffinity Columns.
Mycotoxins are toxic metabolites produced by various species of fungi, mainly belonging to the genera Aspergillus, Penicillium and Fusarium. They usually enter the food chain through contaminated food and feed crops (mainly cereals) and cause serious acute and chronic health effects in humans and animals. Therefore, mycotoxin analysis of food and feed is necessary and often required by law.
Deoxynivalenol (DON, also known as vomitoxin) is a sesquiterpenoid compound found in Fusarium graminearum (roseum), F. culmorum and other species. As one of the most common mycotoxins, DON is commonly found in many plant products, especially in cereal crops such as wheat, corn, barley, oats, and rice.
In the higher and more severe stages of contamination, symptoms associated with vomitoxin are much more severe and include abdominal pain, dizziness, headache, throat irritation, nausea, vomiting, diarrhea, and blood in the stool. In animals, DON-contaminated feed can lead to refusal to eat, vomiting or diarrhea, which can inhibit growth. dON testing is an important preventative tool for maintaining the health and productivity of production animals.
Creative Diagnostics has developed high quality test reagents to support the development of mycotoxin detection. Through years of research and experience of its technical staff, the company has successfully developed a range of antigens and antibodies for use in immunoassays and have established a complete set of mycotoxin detection platforms. The newly released Vomitoxin Test Reagents are manufactured under strict quality control procedures and offer excellent performance.
For example, the Deoxynivalenol (DON) ELISA Kit (DEIA056) can be used for the rapid qualitative and quantitative detection of Deoxynivalenol in grain and feed. This kit adopts "direct competition method" enzyme immunoassay technology and is a new generation of drug residue detection kit. It is fast, convenient, accurate and sensitive. The operation time is only 20 minutes, which can minimize the operation error and workload. It should be noted that this is a laboratory reagent and should not be administered to humans or animals or used as a drug.
Creative Diagnostics is committed to providing high quality and reliable testing solutions to the food and feed industries. The company's new Vomitoxin Test Reagents offer unparalleled accuracy and sensitivity. To learn more information and to explore Creative Diagnostics’ comprehensive product portfolio, please visit https://www.creative-diagnostics.com/food-analysis/tag-don-vomitoxin-34.htm.
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, small molecule conjugates and critical assay reagents for the analysis of food, feed, environmental and toxicological samples. Its product portfolio covers a wide range of analytes including mycotoxins, drug residues, pesticides, contaminants, food allergens, food pathogens and vitamins. The company also assists customers in the rapid development, manufacture and commercialization of small molecule antigens, antibodies and food safety lateral flow strips for any market segment.
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, is proud to announce the launch of its state-of-the-art Anti-AAV Antibody ELISA Kits for the most commonly used AAV serotypes. These kits are designed to accelerate gene therapy research by enabling the accurate detection and quantification of anti-adeno-associated virus (AAV) antibodies.
The first human AAV was identified in 1965 as a contaminant of adenovirus preparations. AAV is one of the smallest viruses, with an envelope-free icosahedral capsid of approximately 22 nm. Although AAV has a high seropositivity rate in humans (approximately 80% of individuals are seropositive for AAV2), the virus has not been associated with any human disease.
AAV gene therapy vectors are capable of infecting both dividing and quiescent cells and can persist in an extrachromosomal state without integrating into the host cell genome, whereas native viruses carry genes that integrate into the host genome. These characteristics make AAV a very attractive candidate viral vector for gene therapy and for modeling homologous human diseases.
Because AAV is of viral origin, its capsid induces cellular and humoral immune responses that lead to neutralization of the vector by anti-AV antibodies, preventing transduction in the patient. Binding antibodies to certain AAV serotypes are present in more than 90% of the population. Some of these antibodies are so neutralizing that they lose their efficacy upon initial administration. Therefore, there is an urgent need to increase awareness of the risk of AAV immunogenicity and to develop techniques to assess and mitigate this response.
Methods for detecting pre-existing AAV immunity include cell-based in vitro TI assays, in vivo (e.g., mouse) TI assays, and enzyme-linked immunosorbent assay (ELISA)-based assays for the detection of total anti-capsid antibody (TAb) assays. TAb assays may be able to detect inefficient NAbs below the threshold of the TI assay, but may not be able to detect non-antibody neutralizing factors.
Creative Diagnostics has developed a series of anti-AAV antibody ELISA kits for the most commonly used AAV serotypes. These standardized assays designed to screen for AAV seropositivity have proven to be an important tool in screening patients for pre-existing antibodies, minimizing safety concerns and improving the efficacy of AAV-based gene therapy.
For example, Anti-AAV9 antibody ELISA Kit (Catalog # DEIASL348) can be used as an analytical tool for qualitative determination of antibodies to AAV9 in serum. Creative Diagnostics’ AAV6 Titration ELISA Kit (Catalog # DEIAAV6) provides a rapid, sensitive and reproducible method for titrating intact wild-type AAV9 viruses, recombinant AAV9 viruses or assembled and intact empty AAV9 capsids.
Creative Diagnostics offers a wide range of quality Anti-AAV Antibody ELISA Kits for gene therapy. For more information on the new products, please visit https://www.creative-diagnostics.com/news-anti-aav-antibody-elisa-kit.htm.
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers’ assay development and manufacturing needs.
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is thrilled to announce the launch of its state-of-the-art Agar Gel Precipitin (AGP) Tests. These in vitro detection tests can be utilized to screen for the presence of multiple pathogens, providing accurate and rapid results for researchers, clinicians, and laboratories worldwide.
AGP tests are based on an antigen-antibody immunoprecipitation reaction in an agar gel and are primarily used for the type-specific identification of viral antigens. These assays are designed to detect serum antibodies specific to influenza virus genus (type) A, i.e., anti-RNA nucleoprotein (i.e., RNP) and matrix protein (M1) antibodies, and are therefore suitable for the identification of influenza viruses. In follow-up studies, AGP is also used to detect Sendai virus and other viruses. Additionally, the AGP test has been the standard monitoring tool for certain viral infections in poultry for many years.
The AGP test is easy to perform and interpret, and many samples can be analyzed in one day. In addition, the test is simple, rapid, specific and not limited by virus subtype. The most commonly used AGP method is the double immunodiffusion method, which not only improves sensitivity, but is also fast, time-saving and more effective for in vitro antiviral detection than the common AGP method.
Recognizing the tremendous potential of AGP testing, Creative Diagnostics leverages its capabilities to provide innovative solutions to researchers worldwide. The company now offers single and double immunodiffusion tests based on the nature and characteristics of the antigen-antibody reaction, which are compatible with many types of viruses, including Adenovirus, Influenza virus, Salmonella enterica serovar Enteritidis, Sendai virus, Poliovirus, and Rabies virus. The AGP test can be applied in vaccine development, antiviral drug screening, epidemiologic studies, and serologic surveillance.
Creative Diagnostics offers AGP tests in several steps. First, a gel matrix is prepared by dissolving agarose powder in a suitable buffer and allowing it to solidify. Next, the target viral antigen is extracted and purified while the corresponding antibodies are obtained. In the immunodiffusion step, wells are made in the gel and antigen and antibody solutions are placed in separate wells. Over time, diffusion occurs, allowing the antigen and antibody to interact. If they react, a visible precipitin ring forms in the gel, indicating the presence of specific antibodies to the viral antigen. Observations are made regarding the number and characteristics of the precipitation rings, and results are analyzed by comparing ring sizes to measure antigen potency relative to a reference. This systematic approach ensures accurate testing and diagnosis.
Creative Diagnostics offers reliable and efficient in vitro detection of viral antigens and remains committed to providing state-of-the-art solutions that support researchers in the fight against viral diseases and improve global health. For more information on the AGP Test, please visit https://antiviral.creative-diagnostics.com/agar-gel-precipitin-tests.html.
About Creative Diagnostics
Headquartered in New York, Creative Diagnostics is a consulting and experimental service provider specializing in virology and microbiology. The company provides comprehensive solutions to conquer obstacles in virology and microbiology research, from high-security infrastructure provision, biosafety regulation elucidation, to expert viral system assistance.
Creative Diagnostics, a leading manufacturer and supplier of antibodies, small molecule conjugates and critical assay reagents for food, feed, environmental and toxicological sample analysis, is pleased to announce the launch of its new Citrinin Test Reagents. These reagents are designed to address the critical need for accurate and reliable detection of Citrinin, a mycotoxin commonly found in stored grains, fruits, and other food products.
Mycotoxins are toxic metabolites produced by various species of fungi, mainly belonging to the genera Aspergillus, Penicillium and Fusarium. They usually enter the food chain through contaminated food and feed crops, mainly cereals. Mycotoxins in food and feed can cause serious acute and chronic health effects in humans and animals. Therefore, mycotoxin analysis of food and feed is necessary and often required by law.
Citrinin is a yellow nephrotoxic mycotoxin produced by fungi such as Penicillium, Aspergillus and Monascus. It is usually found together with another nephrotoxic mycotoxin, ochratoxin A. Citrinin is generally formed under poor post-harvest storage conditions and are found primarily in stored grains, but also in other plant products such as beans, fruits, fruit and vegetable juices, herbs and spices, and spoiled dairy products. It can cause different toxic effects, such as nephrotoxic, hepatotoxic and cytotoxic effects.
The high toxicity and carcinogenicity of mycotoxins and their ability to cause a wide range of pathologies make it necessary to monitor food and feed, which requires reliable analytical methods. A variety of testing solutions are available for the analysis of mycotoxins in food and feed, from rapid tests that are easy to perform to more time-consuming reference method tests that provide more detailed results. Results can be qualitative, semi-quantitative or quantitative.
High performance liquid chromatography (HPLC), enzyme linked immunosorbent assay (ELISA) and lateral flow detection (LFD) are the main methods for mycotoxin analysis. To date, high-performance liquid chromatography with fluorescence detection (HPLC-FLD) is the method of choice for routine citrinin analysis. The limit of detection (LOD) can be as low as 0.1 µg/kg.
Creative Diagnostics now offers a range of Citrinin Test Reagents for the detection of Citrinin, including the Mouse Anti-Citrinin monoclonal antibody, clone CIT (CABT-L2517) and Citrinin [BSA] (DAGPY-0061). These reagents provide a rapid, accurate, and easy-to-use method for detecting citrinin in food and feed products. They are a valuable tool for food safety professionals who want to ensure the safety of their products.
By providing accurate and sensitive detection, Creative Diagnostics empowers scientists to protect consumers from harmful mycotoxins. To learn more about the Citrinin Test Reagents and to explore Creative Diagnostics' comprehensive product portfolio, please visit https://www.creative-diagnostics.com/food-analysis/tag-citrinin-33.htm.
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, small molecule conjugates and critical assay reagents for the analysis of food, feed, environmental and toxicological samples. Its product portfolio covers a wide range of analytes including mycotoxins, drug residues, pesticides, contaminants, food allergens, food pathogens and vitamins. The company also assists customers in the rapid development, manufacture and commercialization of small molecule antigens, antibodies and food safety lateral flow strips for any market segment.
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced its AAV Reagent Solutions to the research community for gene therapy, including a comprehensive collection of AAV Antibodies, AAV Antigens and Anti-AAV Antibody ELISA Kits applicable to gene replacement, gene editing and gene silencing.
The first human adeno-associated virus (AAV) was discovered in 1965, as a contaminant of adenovirus (Ad) preparations. AAV belongs to the family Parvoviridae and is a small, non-enveloped DNA virus with a genome of approximately 4.7 kb, making it one of the smallest viruses. The AAV vector is a gene delivery vehicle modified from the AAV genome. The adeno-associated virus genome has an inverted terminal repeat (ITR) sequence at both ends of the genome, where the D sequence is closely associated with efficient release, selective replication and packaging of the viral genome.
Although several AAV-based gene therapy drugs have been approved, the immunogenicity of AAV vectors remains a significant barrier to the use of these drugs in preclinical and clinical studies. For example, humans and non-human primates exposed to wild-type AAV typically carry anti-shell neutralizing antibodies (NAbs) that cross-react with several different serotypes used for gene transfer. After vector inoculation, anti-AAV NAb develops rapidly at high titers and persists for several years, preventing vector re-administration.
Therefore, a clear definition of the baseline immunological parameters of gene transfer is important to ensure accurate interpretation of preclinical and clinical trial results. Methods for detecting AAV immunity include cell-based in vitro TI assays, in vivo TI assays (e.g., in mice), and total antiviral capsid antibody (TAb) tests based on enzyme-linked immunosorbent assays (ELISA). TAb methods can detect inefficient NAb below the threshold for TI detection, but may not detect non-antibody neutralizing factors. In vivo and in vitro TI assays screen samples for anti-AAV, NAb and other factors that regulate the efficiency of AAV transduction.
Creative Diagnostics offers a comprehensive line of AAV antibodies capable of recognizing the entire viral capsid, as well as antibodies targeting AA viral subunits and replicases. Titration ELISA kits for different AAV subtypes are also available. In addition, Creative Diagnostics has developed a series of anti-AAV antibody ELISA kits for the most commonly used AAV serotypes.
For example, the Anti-AAV2 (intact particle) monoclonal antibody (Catalog # CABT-B9062) can specifically detect intact viral particles, including empty and intact capsids. For AAV2 and AAV3, the antibody recognizes conformational epitopes of assembled phage that are not present in denatured and native unassembled phage proteins. Creative Diagnostics has developed various humanized antibodies that exclusively target intact AAV particles.
Creative Diagnostics offers a wide range of quality AAV antibodies for gene therapy. For more information on the new antibodies, please visit https://www.creative-diagnostics.com/aav-for-gene-therapy.htm.
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers’ assay development and manufacturing needs.